{"gene":"FAS","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1995,"finding":"Upon APO-1/Fas (CD95) oligomerization, cytotoxicity-dependent APO-1-associated proteins (CAP1-4) are recruited to form a death-inducing signaling complex (DISC) with the aggregated receptor. CAP1 and CAP2 were identified as serine-phosphorylated MORT1/FADD. Association required the C-terminal cytoplasmic tail of APO-1 and was abolished by the lpr(cg) amino acid replacement in the death domain.","method":"Immunoprecipitation of APO-1-associated proteins from T and B cell lines after receptor crosslinking; mutant receptor analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP from endogenous proteins, multiple cell lines, functional domain mapping with mutants; foundational DISC paper replicated extensively","pmids":["8521815"],"is_preprint":false},{"year":1996,"finding":"The NMR solution structure of the Fas death domain was determined: it consists of six antiparallel amphipathic alpha-helices in a novel fold. Site-directed mutagenesis identified the surface region involved in death-domain self-association and in binding to the downstream signaling partner FADD.","method":"NMR spectroscopy; site-directed mutagenesis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure determination combined with mutagenesis in a single rigorous study; directly establishes binding interface","pmids":["8967952"],"is_preprint":false},{"year":1998,"finding":"Two distinct CD95 signaling pathways exist: in Type I cells, caspase-8 is activated rapidly and in large amounts at the DISC, bypassing mitochondria (Bcl-2/Bcl-xL overexpression does not block apoptosis); in Type II cells, DISC formation is reduced, caspase activation depends on mitochondrial membrane potential loss (ΔΨm), and Bcl-2/Bcl-xL overexpression blocks both caspase activation and apoptosis.","method":"Kinetic caspase activation assays, Bcl-2/Bcl-xL overexpression, DISC immunoprecipitation, caspase-3 reconstitution in MCF7-Fas cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (DISC IP, caspase assays, genetic overexpression, reconstitution), replicated across multiple cell lines; foundational paper with >2400 citations","pmids":["9501089"],"is_preprint":false},{"year":1994,"finding":"CD95 crosslinking activates an acidic sphingomyelinase (optimal pH 5.0), causing sphingomyelin hydrolysis and ceramide generation. Cell-permeant ceramide analogue C2-ceramide was sufficient to induce apoptosis in CD95-sensitive lines, suggesting ceramide is an early intracellular signal downstream of CD95.","method":"In vivo sphingomyelin hydrolysis assay; direct in vitro enzymatic activity measurement with labeled SM vesicles; ceramide treatment","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct enzymatic assay plus functional rescue with ceramide, single lab; later work showed aSMase is not required in all contexts","pmids":["7523573"],"is_preprint":false},{"year":1995,"finding":"TCR-induced apoptosis in human T cells (Jurkat, alloreactive clone S13, peripheral activated T cells) is mediated by autocrine CD95L: TCR stimulation induces CD95L expression and secretion of soluble CD95L, and apoptosis is blocked by anti-APO-1 antibody fragments or soluble APO-1 receptor decoys.","method":"Functional blocking antibodies; single-cell cultures; soluble receptor decoy competition; CD95L detection in supernatant","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal blocking approaches in multiple human T cell systems; replicated across three T cell models","pmids":["7530335"],"is_preprint":false},{"year":1995,"finding":"Cell surface expression of APO-1 ligand (FasL) is regulated by Zn2+-dependent metalloproteases: metalloprotease inhibitors increase surface FasL accumulation, indicating that metalloprotease cleavage generates the soluble form of FasL and limits membrane-bound FasL.","method":"Immunofluorescence with class-specific protease inhibitors; antibody detection of soluble FasL; Zn2+/Ca2+ modulation","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological inhibitor approach in multiple T cell lines, consistent results, but mechanism inferred from inhibitors rather than direct identification of the metalloprotease","pmids":["7545118"],"is_preprint":false},{"year":1998,"finding":"p53 transcriptionally activates the CD95 receptor gene by binding to a p53-responsive element in the first intron of CD95 and cooperating with promoter elements, thereby upregulating CD95 surface expression in response to DNA-damaging anticancer drugs. This sensitizes cells to CD95-mediated apoptosis. Mutant p53 failed to induce CD95 upregulation.","method":"Reporter gene assays with p53-RE constructs; p53 binding assays; restitution of wt p53 in p53-null cells; temperature-sensitive p53 mutants","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — transcriptional activation demonstrated by multiple reporter constructs, direct p53 binding, functional rescue in p53-null cells, and temperature-sensitive mutant validation","pmids":["9841917"],"is_preprint":false},{"year":1996,"finding":"CD95 engagement activates NF-κB DNA-binding activity independently of its cytotoxic function: a C-terminal 37-amino-acid deletion in the CD95 cytoplasmic domain that abrogates apoptosis only marginally affects NF-κB activation.","method":"Electrophoretic mobility shift assay (EMSA); deletion mutant analysis in multiple cell lines","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus defined deletion mutant, multiple cell lines, single lab","pmids":["8621545"],"is_preprint":false},{"year":1996,"finding":"CD95-triggered activation of stress-activated protein kinases (JNK/SAPK, 46 kDa and 54 kDa) occurs downstream of ICE-like proteases (caspases) and downstream of DISC formation: caspase inhibitor zVAD-fmk and CrmA blocked SAP kinase activation but not DISC formation, placing caspases between DISC and SAP kinases.","method":"Kinase assays (phosphorylation of c-Jun); caspase inhibitor (zVAD-fmk, CrmA overexpression); DISC immunoprecipitation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological epistasis with DISC and caspase assays, single lab, two orthogonal inhibitor approaches","pmids":["8950975"],"is_preprint":false},{"year":1997,"finding":"The FasL homotrimer binds three Fas molecules. Point mutations at the FasL–Fas interaction interface (P206, Y218, F275/gld) reduced or abolished Fas binding and cytotoxicity; F275L (gld equivalent) caused aggregation and loss of Fas binding. Glycosylation of FasL N-linked glycans was required for efficient secretion.","method":"Site-directed mutagenesis of FasL; binding assays with recombinant Fas-Fc fusion; cytotoxicity assays; molecular modeling based on LTα–TNFRI structure","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mutagenesis with functional validation (binding + cytotoxicity), single lab","pmids":["9228058"],"is_preprint":false},{"year":1999,"finding":"In autoimmune lymphoproliferative syndrome (ALPS), heterozygous CD95 death-domain mutations cause structural alterations that abolish FADD/MORT1 binding. Despite heterozygosity, lymphocytes from ALPS patients show markedly reduced FADD association and loss of caspase recruitment after CD95 crosslinking, establishing dominant-negative interference with DISC formation.","method":"Co-IP of FADD with CD95 from patient lymphocytes; caspase recruitment assay; structural analysis of nine independent death-domain mutations","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP from primary patient cells across nine independent mutations, with functional caspase recruitment assay; directly establishes mechanism of dominant-negative interference","pmids":["10200300"],"is_preprint":false},{"year":1997,"finding":"Ceramide links cellular stress responses (gamma-irradiation, doxorubicin) to CD95-mediated apoptosis: ceramide induces CD95L expression and apoptosis; antisense CD95L and dominant-negative FADD block ceramide-induced and stress-induced apoptosis. Fibroblasts from Niemann-Pick type A patients (lacking ceramide synthesis) fail to upregulate CD95L and resist apoptosis after irradiation/doxorubicin but can still undergo apoptosis when directly triggered through CD95.","method":"Antisense CD95L; dominant-negative FADD transfection; genetically deficient NPA fibroblasts; exogenous ceramide rescue","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function (NPA cells, dominant-negative FADD), rescue with exogenous ceramide; single lab, multiple orthogonal approaches","pmids":["9321399"],"is_preprint":false},{"year":1998,"finding":"Fas/CD95-triggered acidic sphingomyelinase activation, ceramide release, and subsequent JNK/p38 kinase activation are regulated downstream of caspases: caspase inhibition (Ac-YVAD-cmk or CrmA) prevented aSMase activation and ceramide generation, placing caspases upstream of aSMase in the CD95 signaling cascade.","method":"Caspase inhibitor (Ac-YVAD-cmk); CrmA transfection; aSMase activity assay; ceramide measurement; JNK/p38 kinase assay","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic (CrmA) caspase inhibition with direct aSMase activity measurement; single lab, two inhibitor approaches","pmids":["10200443"],"is_preprint":false},{"year":2000,"finding":"Acid sphingomyelinase (aSMase) is required for Fas-mediated cell death in hepatocytes but not in thymocytes, T cells, or B cells: aSMase-/- mice showed protection from anti-Fas-induced hepatocyte apoptosis and mortality, while lymphocyte apoptosis and activation-induced cell death were unaffected by aSMase status.","method":"Genetically engineered aSMase-/- mice; in vitro and in vivo anti-Fas antibody challenge; comparison of hepatocyte vs. lymphocyte apoptosis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetically engineered knockout mice, multiple cell types compared, in vivo and in vitro validation; directly establishes tissue-specific role of aSMase","pmids":["10722706"],"is_preprint":false},{"year":2000,"finding":"Ceramide generation downstream of CD95 is initiator-caspase-dependent and occurs during the initiation phase of apoptosis, prior to the effector phase: dominant-negative FADD blocked ceramide generation; CrmA blocked FADD-induced ceramide elevation; limited pro-caspase-8 expression raised ceramide without causing apoptosis.","method":"Titrated FADD transfection in HeLa and 293T cells; dominant-negative FADD; CrmA; diacylglycerol kinase assay; electrospray tandem mass spectrometry for ceramide","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — reconstitution approach with dominant-negative FADD and limited caspase-8 expression, confirmed by mass spectrometry; single lab","pmids":["10722705"],"is_preprint":false},{"year":2003,"finding":"FAP-1 (Fas-associated phosphatase 1) binds the C-terminus of Fas and retains it intracellularly within the cytoskeleton network, reducing cell surface Fas expression. Dominant-negative FAP-1 or FAP-1 siRNA upregulates surface Fas. A Fas C275 mutation decreases FAP-1 association and increases Fas surface export.","method":"FAP-1 overexpression/dominant-negative transfection; siRNA knockdown; flow cytometry for surface Fas; confocal microscopy; mutation analysis","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic perturbations (overexpression, dominant-negative, siRNA) with direct surface expression readout; single lab, two orthogonal approaches","pmids":["12724420"],"is_preprint":false},{"year":2012,"finding":"FAS/CD95 mediates noncanonical IL-1β and IL-18 maturation in macrophages and dendritic cells via caspase-8 activation, independently of inflammasomes or RIP3. TLR ligand priming upregulates Fas expression and renders cells responsive to FasL-mediated caspase-8 activation and IL-1β/IL-18 processing.","method":"Genetic knockout cells (RIP3-/-, caspase-1-/-); FasL stimulation of macrophages and DCs; IL-1β/IL-18 maturation assay; caspase-8 activation assay","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic knockouts (inflammasome, RIP3) with direct cytokine maturation and caspase-8 activation readouts; establishes novel non-apoptotic pathway","pmids":["23144495"],"is_preprint":false},{"year":2013,"finding":"Fas/CD95-induced apoptosis is accompanied by production of chemokines (MCP-1, IL-8, CXCL1, IL-6, GMCSF) that serve as 'find-me' signals promoting phagocyte chemotaxis toward apoptotic cells. RIPK1 and IAPs are required for optimal Fas-induced cytokine/chemokine production; IAP antagonists suppress this proinflammatory response.","method":"Cytokine/chemokine profiling after Fas stimulation; chemotaxis assay; RIPK1 knockdown; IAP antagonist treatment; phagocyte recruitment assay","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional chemotaxis assay linked to specific mediators; genetic (RIPK1 KD) and pharmacological (IAP antagonist) perturbations; single lab","pmids":["23434371"],"is_preprint":false},{"year":1998,"finding":"Nitric oxide (NO) inhibits APO-1/Fas-mediated apoptosis by S-nitrosylating caspase-8 and caspase-1, preventing their activation. NO blocks proteolytic cleavage of caspase-3 upstream of its activation. The effect is cGMP-independent and also inhibits apoptosis induced by FADD overexpression.","method":"NO donor and inducible NOS transfection; caspase-3 cleavage assay; caspase-8 S-nitrosylation assay; FADD overexpression apoptosis assay; 8-bromo-cGMP control","journal":"Cell growth & differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct caspase S-nitrosylation demonstrated, multiple mechanistic levels tested; single lab","pmids":["9607562"],"is_preprint":false},{"year":2000,"finding":"Human and mouse Fas/CD95 genes each contain a p53-responsive element (p53RE) in the first intron that is specifically bound by p53 and functions as a p53-dependent enhancer. Unlike the bax p53RE, the Fas p53RE is activated by p53 mutants that cannot induce apoptosis (Pro-175 and Ala-143), suggesting Fas upregulation by p53 sensitizes to apoptosis rather than directly inducing it.","method":"Reporter gene assays in mammalian and yeast systems; p53 binding assays; discriminatory p53 mutant analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct p53 binding and transcriptional activation assays with defined mutants; functional distinction from bax established; single lab","pmids":["10660538"],"is_preprint":false},{"year":2009,"finding":"TAp63 and TAp73 isoforms of the p53 family, in addition to wt p53, transactivate the CD95/FAS gene through the intronic p53-responsive element and promoter p53-REs, with cooperation between intronic and promoter elements required for maximal transcriptional activation.","method":"Reporter gene assays with p53-RE constructs; p63/p73 isoform expression","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct transcriptional reporter assay with defined p53-family members; single lab, single method","pmids":["19615968"],"is_preprint":false},{"year":1996,"finding":"A novel ubiquitin-conjugating enzyme (UBC-FAP/HsUbc9) associates with the Fas death domain. A single amino acid substitution in the Fas death domain that abolishes apoptosis also abolishes Fas–UBC-FAP association, suggesting UBC-FAP may participate in Fas signal transduction.","method":"Yeast two-hybrid screen; co-immunoprecipitation; complementation of ubc9-1 yeast mutant; death-domain point mutant analysis","journal":"The Journal of biological chemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single pulldown/Co-IP with no downstream functional validation of the interaction in Fas signaling; association correlates with apoptosis competence but causality not established","pmids":["8940097"],"is_preprint":false},{"year":2005,"finding":"CD47 (integrin-associated protein) physically associates with Fas upon Fas activation and augments Fas-mediated apoptosis: Jurkat cells lacking CD47 are resistant to Fas-mediated death and show impaired caspase activation, cytochrome c release, loss of mitochondrial membrane potential, and DNA cleavage downstream of Fas engagement.","method":"CD47-deficient Jurkat cells; anti-Fas co-immunoprecipitation showing Fas–CD47 association; caspase and PARP cleavage assays; mitochondrial membrane potential assay; CD47-null primary mouse T cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP showing direct association plus loss-of-function phenotype in both cell lines and primary CD47-/- T cells; single lab","pmids":["15917238"],"is_preprint":false},{"year":1998,"finding":"Protein kinase C (PKC) inhibits CD95 receptor oligomerization at the cell surface as a mechanism for restraining CD95-mediated apoptosis; PKC activation diminishes CD95 aggregation induced by agonistic antibodies and UVB-induced CD95 oligomerization and apoptosis in Jurkat T cells.","method":"PKC activators (PMA) and inhibitors; CD95 aggregation assay; UVB-induced apoptosis; MAP kinase pathway inhibition","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor oligomerization directly measured with pharmacological modulation plus two independent stimuli (agonist Ab and UV); single lab","pmids":["10528172"],"is_preprint":false},{"year":2016,"finding":"Fas-mediated apoptosis in primary mouse T cells, B cells, and dendritic cells requires receptor palmitoylation at Cys194 for lipid raft localization: a palmitoylation-defective Fas C194V mutant fails to efficiently induce apoptosis in primary immune cells despite retaining ability to enhance T-cell differentiation and to prevent lymphoaccumulation and autoimmunity.","method":"Knock-in C194V mutant mice; palmitoylation assay; lipid raft fractionation; apoptosis assays in primary immune cells; lymphoproliferation phenotype analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knock-in mutant with multiple primary cell types tested, multiple functional readouts (apoptosis, raft localization, autoimmunity); single lab but multiple orthogonal methods","pmids":["28008916"],"is_preprint":false},{"year":2003,"finding":"Fas (CD95) ligation on human monocytes induces proinflammatory cytokine (TNF-α, IL-8) production and NF-κB nuclear translocation through a caspase-dependent mechanism, while in monocyte-derived macrophages Fas-induced cytokine responses occur without apoptosis and are caspase-independent, demonstrating maturation-dependent divergence in Fas signaling.","method":"Fas ligation on primary monocytes and macrophages; ELISA for TNF-α and IL-8; NF-κB nuclear translocation; caspase inhibitor treatment; neutrophil chemotaxis assay","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — primary human cells with pharmacological dissection; two distinct cell maturation states compared; single lab","pmids":["12794152"],"is_preprint":false}],"current_model":"FAS/CD95 is a death receptor that, upon oligomerization by FasL, recruits FADD/MORT1 via death-domain interactions to form the DISC (death-inducing signaling complex), which activates caspase-8; in Type I cells sufficient caspase-8 at the DISC directly activates effector caspase-3 independent of mitochondria, whereas in Type II cells limited DISC activity requires amplification through the mitochondrial pathway (sensitive to Bcl-2/Bcl-xL); FAS surface expression is transcriptionally induced by p53 (and TAp63/TAp73) via intronic and promoter p53-responsive elements, regulated post-translationally by FAP-1 (which retains Fas intracellularly) and palmitoylation at Cys194 (required for lipid raft localization and efficient apoptosis in primary immune cells); CD95 additionally triggers non-apoptotic signals including NF-κB activation, JNK/SAP kinase activation (via caspases), ceramide generation (via caspase-dependent aSMase activation, tissue-dependent), and caspase-8-dependent maturation of IL-1β/IL-18 in myeloid cells."},"narrative":{"mechanistic_narrative":"FAS (APO-1/CD95) is a death-domain-containing receptor that initiates apoptosis when oligomerized by trimeric FasL, nucleating a death-inducing signaling complex (DISC) in which the receptor C-terminal cytoplasmic tail recruits serine-phosphorylated FADD/MORT1 and downstream caspase-8 [PMID:8521815, PMID:9228058]. NMR structure determination of the Fas death domain (six antiparallel amphipathic α-helices) mapped the self-association and FADD-binding surface, and disruption of this interface—by the lpr(cg) substitution or by death-domain mutations—abolishes FADD recruitment and signaling [PMID:8967952, PMID:8521815]. Heterozygous death-domain mutations that block FADD binding cause autoimmune lymphoproliferative syndrome (ALPS) through dominant-negative interference with DISC formation [PMID:10200300]. Two signaling tiers exist: in Type I cells abundant DISC-generated caspase-8 directly drives effector caspases independently of mitochondria, whereas in Type II cells limited DISC activity requires mitochondrial amplification and is blocked by Bcl-2/Bcl-xL [PMID:9501089]. FAS surface availability is set transcriptionally—p53, and the family members TAp63/TAp73, transactivate FAS via an intronic p53-responsive element cooperating with promoter elements, sensitizing cells to apoptosis [PMID:9841917, PMID:10660538, PMID:19615968]—and post-translationally, with FAP-1 retaining Fas intracellularly to limit surface expression and Cys194 palmitoylation required for lipid-raft localization and efficient apoptosis in primary immune cells [PMID:12724420, PMID:28008916]. Beyond death, FAS triggers non-apoptotic outputs including caspase-dependent JNK/SAPK activation, caspase-dependent acidic-sphingomyelinase activation and ceramide generation that is tissue-restricted (required in hepatocytes but not lymphocytes), NF-κB activation, and caspase-8-dependent maturation of IL-1β/IL-18 in myeloid cells [PMID:8950975, PMID:10200443, PMID:10722706, PMID:23144495].","teleology":[{"year":1994,"claim":"Established that CD95 engagement generates a lipid second messenger, linking receptor ligation to ceramide-based signaling before the DISC was defined.","evidence":"In vivo and in vitro acidic sphingomyelinase activity assays plus C2-ceramide treatment in CD95-sensitive lines","pmids":["7523573"],"confidence":"Medium","gaps":["Did not place aSMase activation relative to caspases","Tissue dependence of ceramide requirement not addressed"]},{"year":1995,"claim":"Defined the physical basis of FAS signal initiation by identifying the DISC and FADD/MORT1 as the recruited adaptor, answering how an oligomerized receptor transmits a death signal.","evidence":"Co-IP of APO-1-associated proteins after receptor crosslinking in T/B cell lines with mutant receptor mapping","pmids":["8521815"],"confidence":"High","gaps":["Caspase-8 not yet shown as the enzymatic effector at the DISC","Quantitative differences between cell types not resolved"]},{"year":1995,"claim":"Demonstrated that FAS drives physiological activation-induced T cell death via an autocrine FasL loop, defining a functional context for the pathway.","evidence":"Blocking antibody fragments and soluble receptor decoys in Jurkat and primary T cell systems","pmids":["7530335"],"confidence":"High","gaps":["Did not address surface vs soluble ligand control","In vivo relevance beyond cultured T cells not tested here"]},{"year":1995,"claim":"Showed that membrane FasL availability is post-translationally controlled by metalloprotease shedding, distinguishing membrane-bound from soluble ligand.","evidence":"Class-specific protease inhibitors with detection of soluble FasL in T cell lines","pmids":["7545118"],"confidence":"Medium","gaps":["The responsible metalloprotease was not directly identified","Mechanism inferred pharmacologically"]},{"year":1996,"claim":"Provided the atomic structure of the Fas death domain and mapped the interaction surface, explaining how DISC-disrupting mutations act.","evidence":"NMR solution structure with site-directed mutagenesis","pmids":["8967952"],"confidence":"High","gaps":["Structure of the death-domain:FADD complex not solved here","Higher-order oligomer geometry not defined"]},{"year":1996,"claim":"Separated FAS apoptotic from non-apoptotic signaling by showing NF-κB activation persists when a cytotoxicity-required tail segment is deleted.","evidence":"EMSA with C-terminal deletion mutants across multiple cell lines","pmids":["8621545"],"confidence":"Medium","gaps":["Adaptors mediating the NF-κB branch not identified","Physiological consequences not defined"]},{"year":1996,"claim":"Identified a candidate death-domain-associated ubiquitin-conjugating enzyme (UBC-FAP/Ubc9), raising the possibility of conjugation enzymes in FAS signaling.","evidence":"Yeast two-hybrid and co-IP with death-domain point mutant correlation","pmids":["8940097"],"confidence":"Low","gaps":["Single pulldown without functional validation of the interaction in FAS signaling","Causal role in apoptosis not established"]},{"year":1996,"claim":"Placed JNK/SAPK activation downstream of caspases and the DISC, ordering a stress-kinase branch of FAS signaling.","evidence":"c-Jun kinase assays with zVAD-fmk/CrmA epistasis and DISC IP","pmids":["8950975"],"confidence":"Medium","gaps":["The specific caspase and kinase intermediates not pinned down","Downstream transcriptional outputs not mapped"]},{"year":1997,"claim":"Defined the FasL trimer–Fas binding stoichiometry and interface, and the glycosylation requirement for ligand secretion.","evidence":"FasL mutagenesis with Fas-Fc binding and cytotoxicity assays, modeled on LTα–TNFRI","pmids":["9228058"],"confidence":"Medium","gaps":["No co-crystal structure of the Fas–FasL complex","Single lab, modeling-based interface"]},{"year":1997,"claim":"Connected genotoxic stress to FAS by showing ceramide induces CD95L expression and FADD-dependent apoptosis, embedding FAS in a stress-response loop.","evidence":"Antisense CD95L, dominant-negative FADD, and Niemann-Pick A fibroblasts with ceramide rescue","pmids":["9321399"],"confidence":"Medium","gaps":["Direct receptor-level apoptosis remained intact in NPA cells, limiting generality","Quantitative ceramide thresholds not defined"]},{"year":1998,"claim":"Resolved the Type I/Type II dichotomy, explaining why mitochondrial amplification (and Bcl-2 sensitivity) governs apoptosis in some cells but not others.","evidence":"Kinetic caspase assays, Bcl-2/Bcl-xL overexpression, DISC IP, and caspase-3 reconstitution in MCF7-Fas cells","pmids":["9501089"],"confidence":"High","gaps":["Molecular determinant of Type I vs Type II identity not defined here","Did not identify what limits DISC formation in Type II cells"]},{"year":1998,"claim":"Established p53 as a transcriptional inducer of FAS through an intronic p53-RE, linking DNA-damage responses to FAS-mediated drug sensitivity.","evidence":"Reporter assays, p53 binding, wt-p53 restitution in p53-null cells, and temperature-sensitive mutants","pmids":["9841917"],"confidence":"High","gaps":["Did not separate sensitization from direct induction","Other transcription factors at the locus not surveyed"]},{"year":1998,"claim":"Identified NO-mediated S-nitrosylation of caspase-8/-1 as a brake on FAS apoptosis acting at the caspase level.","evidence":"NO donors and iNOS transfection with caspase cleavage and S-nitrosylation assays, cGMP-independent","pmids":["9607562"],"confidence":"Medium","gaps":["Physiological NO sources controlling FAS not defined","Single lab"]},{"year":1998,"claim":"Showed PKC restrains FAS by inhibiting receptor oligomerization at the surface, defining a pre-DISC regulatory node.","evidence":"PKC activators/inhibitors with CD95 aggregation and UVB-apoptosis readouts in Jurkat cells","pmids":["10528172"],"confidence":"Medium","gaps":["Direct PKC substrate on the oligomerization machinery not identified","Single cell system"]},{"year":2000,"claim":"Ordered the ceramide branch by placing aSMase activation downstream of initiator caspases during the initiation phase of apoptosis.","evidence":"Dominant-negative FADD and CrmA with aSMase activity, ceramide, and JNK/p38 assays; titrated caspase-8 expression and mass spectrometry","pmids":["10200443","10722705"],"confidence":"Medium","gaps":["Direct caspase substrate activating aSMase not identified","Single lab"]},{"year":2000,"claim":"Defined the ceramide pathway as tissue-restricted, showing aSMase is required for FAS-induced hepatocyte but not lymphocyte death.","evidence":"aSMase-/- mice challenged with anti-Fas in vivo and in vitro, comparing hepatocytes and lymphocytes","pmids":["10722706"],"confidence":"High","gaps":["Molecular basis of the hepatocyte-specific requirement not defined","Did not address aSMase role in non-apoptotic FAS signaling"]},{"year":2000,"claim":"Showed the intronic FAS p53-RE is engaged even by apoptosis-defective p53 mutants, distinguishing FAS as a sensitization rather than direct apoptosis-inducing target.","evidence":"Reporter and p53 binding assays in mammalian and yeast systems with discriminatory p53 mutants","pmids":["10660538"],"confidence":"Medium","gaps":["Endogenous chromatin context not tested","Single lab"]},{"year":2003,"claim":"Identified FAP-1 as a post-translational regulator that retains Fas intracellularly and limits surface expression, with Cys275 controlling the interaction.","evidence":"FAP-1 overexpression, dominant-negative, and siRNA with surface-Fas flow cytometry, confocal microscopy, and mutation analysis","pmids":["12724420"],"confidence":"Medium","gaps":["Mechanism of cytoskeletal retention not detailed","In vivo relevance not addressed"]},{"year":2003,"claim":"Revealed maturation-dependent divergence of FAS signaling in myeloid cells: caspase-dependent cytokine output in monocytes versus caspase-independent responses in macrophages.","evidence":"Fas ligation on primary monocytes/macrophages with cytokine ELISA, NF-κB translocation, and caspase inhibitors","pmids":["12794152"],"confidence":"Medium","gaps":["Molecular switch underlying maturation-state divergence not defined","Single lab"]},{"year":2005,"claim":"Identified CD47 as a Fas-associated co-factor that augments Fas apoptosis via the mitochondrial branch.","evidence":"CD47-deficient Jurkat and CD47-null primary T cells with Fas–CD47 co-IP, caspase/PARP cleavage, cytochrome c release, and ΔΨm assays","pmids":["15917238"],"confidence":"Medium","gaps":["Whether the Fas–CD47 association is direct vs complex-mediated not resolved","Structural basis not defined"]},{"year":2012,"claim":"Established a non-apoptotic FAS function: caspase-8-dependent IL-1β/IL-18 maturation in myeloid cells independent of inflammasomes or RIP3.","evidence":"RIP3-/- and caspase-1-/- cells with FasL stimulation, cytokine maturation, and caspase-8 activation assays","pmids":["23144495"],"confidence":"High","gaps":["Direct caspase-8 substrate for cytokine processing not pinned down","In vivo contribution to inflammation not quantified"]},{"year":2013,"claim":"Showed FAS-induced apoptosis is proinflammatory, generating chemokine 'find-me' signals requiring RIPK1 and IAPs.","evidence":"Cytokine/chemokine profiling, chemotaxis and phagocyte recruitment assays with RIPK1 knockdown and IAP antagonists","pmids":["23434371"],"confidence":"Medium","gaps":["Mechanism coupling RIPK1/IAPs to specific chemokines not detailed","Single lab"]},{"year":2016,"claim":"Demonstrated that Cys194 palmitoylation drives Fas into lipid rafts and is required for efficient apoptosis in primary immune cells, separating death from non-apoptotic functions in vivo.","evidence":"C194V knock-in mice with palmitoylation assay, raft fractionation, primary-cell apoptosis, and autoimmunity phenotyping","pmids":["28008916"],"confidence":"High","gaps":["The palmitoyl transferase acting on Fas not identified","How raft localization mechanistically enhances DISC assembly not resolved"]},{"year":null,"claim":"The molecular determinant that assigns cells to Type I versus Type II FAS signaling, and the rules governing the switch between apoptotic and the diverse non-apoptotic outputs (NF-κB, JNK, ceramide, cytokine maturation), remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined factor predicting Type I vs Type II identity","Switch between death and inflammatory/proliferative outputs not mechanistically specified","Palmitoyl transferase and raft-assembly machinery for Fas unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,9]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[15,24,23]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,2,10]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,16,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,8]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,19,20]}],"complexes":["DISC (death-inducing signaling complex)"],"partners":["FADD","FASL","FAP1","CD47","CASP8"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P25445","full_name":"Tumor necrosis factor receptor superfamily member 6","aliases":["Apo-1 antigen","Apoptosis-mediating surface antigen FAS","FASLG receptor"],"length_aa":335,"mass_kda":37.7,"function":"Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase CASP8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs CASP8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P25445/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FAS","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FAS","total_profiled":1310},"omim":[{"mim_id":"621019","title":"PRE-mRNA-PROCESSING FACTOR 40 HOMOLOG B; PRPF40B","url":"https://www.omim.org/entry/621019"},{"mim_id":"621013","title":"TETRASPANIN 11; TSPAN11","url":"https://www.omim.org/entry/621013"},{"mim_id":"621004","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 4; ADMIO4","url":"https://www.omim.org/entry/621004"},{"mim_id":"620696","title":"RBPJ-INTERACTING AND TUBULIN-ASSOCIATED PROTEIN 1; RITA1","url":"https://www.omim.org/entry/620696"},{"mim_id":"620640","title":"RING FINGER PROTEIN 145; RNF145","url":"https://www.omim.org/entry/620640"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FAS"},"hgnc":{"alias_symbol":["CD95","APO-1"],"prev_symbol":["FAS1","APT1","TNFRSF6"]},"alphafold":{"accession":"P25445","domains":[{"cath_id":"2.10.50.10","chopping":"56-127","consensus_level":"medium","plddt":94.1215,"start":56,"end":127},{"cath_id":"-","chopping":"132-167","consensus_level":"medium","plddt":92.7831,"start":132,"end":167},{"cath_id":"1.10.533.10","chopping":"230-334","consensus_level":"high","plddt":85.475,"start":230,"end":334}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25445","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25445-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25445-F1-predicted_aligned_error_v6.png","plddt_mean":77.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FAS","jax_strain_url":"https://www.jax.org/strain/search?query=FAS"},"sequence":{"accession":"P25445","fasta_url":"https://rest.uniprot.org/uniprotkb/P25445.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25445/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25445"}},"corpus_meta":[{"pmid":"9501089","id":"PMC_9501089","title":"Two CD95 (APO-1/Fas) signaling pathways.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9501089","citation_count":2423,"is_preprint":false},{"pmid":"8521815","id":"PMC_8521815","title":"Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8521815","citation_count":1732,"is_preprint":false},{"pmid":"7530335","id":"PMC_7530335","title":"Autocrine T-cell suicide mediated by APO-1/(Fas/CD95).","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7530335","citation_count":1555,"is_preprint":false},{"pmid":"8910274","id":"PMC_8910274","title":"Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8910274","citation_count":1075,"is_preprint":false},{"pmid":"8616718","id":"PMC_8616718","title":"Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.","date":"1996","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8616718","citation_count":931,"is_preprint":false},{"pmid":"12655293","id":"PMC_12655293","title":"The CD95(APO-1/Fas) DISC and beyond.","date":"2003","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/12655293","citation_count":839,"is_preprint":false},{"pmid":"8946836","id":"PMC_8946836","title":"Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?","date":"1996","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8946836","citation_count":833,"is_preprint":false},{"pmid":"9841917","id":"PMC_9841917","title":"p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.","date":"1998","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9841917","citation_count":714,"is_preprint":false},{"pmid":"8557033","id":"PMC_8557033","title":"Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8557033","citation_count":664,"is_preprint":false},{"pmid":"7595193","id":"PMC_7595193","title":"Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7595193","citation_count":629,"is_preprint":false},{"pmid":"7523573","id":"PMC_7523573","title":"Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7523573","citation_count":527,"is_preprint":false},{"pmid":"8760796","id":"PMC_8760796","title":"Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8760796","citation_count":508,"is_preprint":false},{"pmid":"9794832","id":"PMC_9794832","title":"Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis.","date":"1998","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9794832","citation_count":402,"is_preprint":false},{"pmid":"9288794","id":"PMC_9288794","title":"The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9288794","citation_count":397,"is_preprint":false},{"pmid":"8967952","id":"PMC_8967952","title":"NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8967952","citation_count":314,"is_preprint":false},{"pmid":"9354463","id":"PMC_9354463","title":"Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9354463","citation_count":306,"is_preprint":false},{"pmid":"9321399","id":"PMC_9321399","title":"Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9321399","citation_count":266,"is_preprint":false},{"pmid":"22075988","id":"PMC_22075988","title":"Regulation of CD95/Fas signaling at the DISC.","date":"2011","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/22075988","citation_count":265,"is_preprint":false},{"pmid":"23144495","id":"PMC_23144495","title":"Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23144495","citation_count":257,"is_preprint":false},{"pmid":"8879222","id":"PMC_8879222","title":"Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8879222","citation_count":251,"is_preprint":false},{"pmid":"9207274","id":"PMC_9207274","title":"CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis.","date":"1997","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/9207274","citation_count":221,"is_preprint":false},{"pmid":"11141488","id":"PMC_11141488","title":"Fas (CD95) induces alveolar epithelial cell apoptosis in vivo: implications for acute pulmonary inflammation.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11141488","citation_count":219,"is_preprint":false},{"pmid":"10391683","id":"PMC_10391683","title":"Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10391683","citation_count":210,"is_preprint":false},{"pmid":"9788963","id":"PMC_9788963","title":"Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis.","date":"1998","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9788963","citation_count":209,"is_preprint":false},{"pmid":"10952962","id":"PMC_10952962","title":"Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia.","date":"2000","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/10952962","citation_count":198,"is_preprint":false},{"pmid":"7545118","id":"PMC_7545118","title":"Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7545118","citation_count":195,"is_preprint":false},{"pmid":"7545115","id":"PMC_7545115","title":"Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7545115","citation_count":189,"is_preprint":false},{"pmid":"9516135","id":"PMC_9516135","title":"Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9516135","citation_count":187,"is_preprint":false},{"pmid":"8612534","id":"PMC_8612534","title":"Fas/APO-1/CD95 system as a mediator of granulosa cell apoptosis in ovarian follicle atresia.","date":"1996","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8612534","citation_count":186,"is_preprint":false},{"pmid":"7542501","id":"PMC_7542501","title":"Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7542501","citation_count":186,"is_preprint":false},{"pmid":"23434371","id":"PMC_23434371","title":"Fas/CD95-induced chemokines can serve as \"find-me\" signals for apoptotic cells.","date":"2013","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/23434371","citation_count":184,"is_preprint":false},{"pmid":"9369415","id":"PMC_9369415","title":"Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells.","date":"1997","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9369415","citation_count":179,"is_preprint":false},{"pmid":"11337030","id":"PMC_11337030","title":"Death the Fas way: regulation and pathophysiology of CD95 and its ligand.","date":"2000","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/11337030","citation_count":173,"is_preprint":false},{"pmid":"9228058","id":"PMC_9228058","title":"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9228058","citation_count":165,"is_preprint":false},{"pmid":"10200300","id":"PMC_10200300","title":"Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10200300","citation_count":150,"is_preprint":false},{"pmid":"12794152","id":"PMC_12794152","title":"Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12794152","citation_count":143,"is_preprint":false},{"pmid":"9177438","id":"PMC_9177438","title":"Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.","date":"1997","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9177438","citation_count":140,"is_preprint":false},{"pmid":"7540953","id":"PMC_7540953","title":"Fas/APO-1 gene transfer for human malignant glioma.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7540953","citation_count":135,"is_preprint":false},{"pmid":"8621545","id":"PMC_8621545","title":"The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8621545","citation_count":128,"is_preprint":false},{"pmid":"8950975","id":"PMC_8950975","title":"CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases.","date":"1996","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8950975","citation_count":125,"is_preprint":false},{"pmid":"7495753","id":"PMC_7495753","title":"Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo.","date":"1995","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7495753","citation_count":123,"is_preprint":false},{"pmid":"9407969","id":"PMC_9407969","title":"Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9407969","citation_count":122,"is_preprint":false},{"pmid":"10972965","id":"PMC_10972965","title":"Fas (CD95/APO-1) plays a role in the pathophysiology of focal cerebral ischemia.","date":"2000","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/10972965","citation_count":122,"is_preprint":false},{"pmid":"9573032","id":"PMC_9573032","title":"Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9573032","citation_count":119,"is_preprint":false},{"pmid":"10203687","id":"PMC_10203687","title":"Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells.","date":"1998","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/10203687","citation_count":118,"is_preprint":false},{"pmid":"9207432","id":"PMC_9207432","title":"Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9207432","citation_count":118,"is_preprint":false},{"pmid":"10722706","id":"PMC_10722706","title":"Role of acidic sphingomyelinase in Fas/CD95-mediated cell death.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10722706","citation_count":116,"is_preprint":false},{"pmid":"10362803","id":"PMC_10362803","title":"Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10362803","citation_count":112,"is_preprint":false},{"pmid":"10660538","id":"PMC_10660538","title":"Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10660538","citation_count":109,"is_preprint":false},{"pmid":"10397246","id":"PMC_10397246","title":"Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10397246","citation_count":109,"is_preprint":false},{"pmid":"10200443","id":"PMC_10200443","title":"Fas/CD95/Apo-I activates the acidic sphingomyelinase via caspases.","date":"1998","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/10200443","citation_count":108,"is_preprint":false},{"pmid":"7585627","id":"PMC_7585627","title":"Expression of Fas/APO-1 during the progression of astrocytomas.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7585627","citation_count":100,"is_preprint":false},{"pmid":"10553053","id":"PMC_10553053","title":"Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10553053","citation_count":95,"is_preprint":false},{"pmid":"9516458","id":"PMC_9516458","title":"CD95 (Fas/APO-1) induces ceramide formation and apoptosis in the absence of a functional acid sphingomyelinase.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9516458","citation_count":94,"is_preprint":false},{"pmid":"12724420","id":"PMC_12724420","title":"FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12724420","citation_count":88,"is_preprint":false},{"pmid":"14563113","id":"PMC_14563113","title":"Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system.","date":"2003","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14563113","citation_count":86,"is_preprint":false},{"pmid":"17180078","id":"PMC_17180078","title":"CD95 (APO-1/Fas)-associating signalling proteins.","date":"1996","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/17180078","citation_count":80,"is_preprint":false},{"pmid":"7540067","id":"PMC_7540067","title":"Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7540067","citation_count":79,"is_preprint":false},{"pmid":"10092091","id":"PMC_10092091","title":"NF-kappaB regulates Fas/APO-1/CD95- and TCR- mediated apoptosis of T lymphocytes.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10092091","citation_count":78,"is_preprint":false},{"pmid":"9607562","id":"PMC_9607562","title":"Nitric oxide inhibits APO-1/Fas-mediated cell death.","date":"1998","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/9607562","citation_count":78,"is_preprint":false},{"pmid":"14563115","id":"PMC_14563115","title":"Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology.","date":"2003","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14563115","citation_count":77,"is_preprint":false},{"pmid":"9761749","id":"PMC_9761749","title":"Expression of Fas (CD95) and FasL (CD95L) in human airway epithelium.","date":"1998","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9761749","citation_count":74,"is_preprint":false},{"pmid":"10722705","id":"PMC_10722705","title":"CD95(Fas/APO-1) signals ceramide generation independent of the effector stage of apoptosis.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10722705","citation_count":74,"is_preprint":false},{"pmid":"10671224","id":"PMC_10671224","title":"T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10671224","citation_count":73,"is_preprint":false},{"pmid":"16159946","id":"PMC_16159946","title":"Fas (CD95)-related apoptosis and rheumatoid arthritis.","date":"2005","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16159946","citation_count":67,"is_preprint":false},{"pmid":"9335379","id":"PMC_9335379","title":"Expression and function of Fas (CD95) on human renal tubular epithelial cells.","date":"1997","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/9335379","citation_count":67,"is_preprint":false},{"pmid":"9054667","id":"PMC_9054667","title":"Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines.","date":"1997","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/9054667","citation_count":66,"is_preprint":false},{"pmid":"29032605","id":"PMC_29032605","title":"Nonapoptotic functions of Fas/CD95 in the immune response.","date":"2017","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/29032605","citation_count":65,"is_preprint":false},{"pmid":"15917238","id":"PMC_15917238","title":"CD47 augments Fas/CD95-mediated apoptosis.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15917238","citation_count":65,"is_preprint":false},{"pmid":"7528670","id":"PMC_7528670","title":"The APO-1/Fas (CD95) receptor is expressed in homozygous MRL/lpr mice.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7528670","citation_count":63,"is_preprint":false},{"pmid":"9547792","id":"PMC_9547792","title":"Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications.","date":"1998","source":"Molecular medicine today","url":"https://pubmed.ncbi.nlm.nih.gov/9547792","citation_count":63,"is_preprint":false},{"pmid":"15280387","id":"PMC_15280387","title":"Carbon monoxide promotes Fas/CD95-induced apoptosis in Jurkat cells.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15280387","citation_count":62,"is_preprint":false},{"pmid":"10208976","id":"PMC_10208976","title":"Death receptor Fas/Apo-1/CD95 expressed by human placental cytotrophoblasts does not mediate apoptosis.","date":"1999","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/10208976","citation_count":61,"is_preprint":false},{"pmid":"12140383","id":"PMC_12140383","title":"Frequent downregulation of Fas (CD95) expression and function in melanoma.","date":"2002","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/12140383","citation_count":60,"is_preprint":false},{"pmid":"9699671","id":"PMC_9699671","title":"Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9699671","citation_count":60,"is_preprint":false},{"pmid":"28008916","id":"PMC_28008916","title":"Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28008916","citation_count":59,"is_preprint":false},{"pmid":"9600216","id":"PMC_9600216","title":"Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas.","date":"1998","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/9600216","citation_count":58,"is_preprint":false},{"pmid":"16917513","id":"PMC_16917513","title":"Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis.","date":"2006","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/16917513","citation_count":56,"is_preprint":false},{"pmid":"7544648","id":"PMC_7544648","title":"Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7544648","citation_count":55,"is_preprint":false},{"pmid":"10728678","id":"PMC_10728678","title":"CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10728678","citation_count":54,"is_preprint":false},{"pmid":"10029626","id":"PMC_10029626","title":"Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation.","date":"1999","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/10029626","citation_count":53,"is_preprint":false},{"pmid":"8940097","id":"PMC_8940097","title":"Association of human fas (CD95) with a ubiquitin-conjugating enzyme (UBC-FAP).","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8940097","citation_count":53,"is_preprint":false},{"pmid":"11465715","id":"PMC_11465715","title":"Regulation of CD95 (Fas/APO-1)-induced apoptosis in human chondrocytes.","date":"2001","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/11465715","citation_count":51,"is_preprint":false},{"pmid":"8671589","id":"PMC_8671589","title":"Comparison of Fas(Apo-1/CD95)- and perforin-mediated cytotoxicity in primary T lymphocytes.","date":"1996","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8671589","citation_count":51,"is_preprint":false},{"pmid":"10528172","id":"PMC_10528172","title":"Protein kinase C inhibits CD95 (Fas/APO-1)-mediated apoptosis by at least two different mechanisms in Jurkat T cells.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10528172","citation_count":51,"is_preprint":false},{"pmid":"8566045","id":"PMC_8566045","title":"Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8566045","citation_count":50,"is_preprint":false},{"pmid":"21209208","id":"PMC_21209208","title":"Fas/CD95 regulatory protein Faim2 is neuroprotective after transient brain ischemia.","date":"2011","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21209208","citation_count":45,"is_preprint":false},{"pmid":"9470847","id":"PMC_9470847","title":"Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue.","date":"1997","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/9470847","citation_count":45,"is_preprint":false},{"pmid":"9694505","id":"PMC_9694505","title":"CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells.","date":"1998","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9694505","citation_count":45,"is_preprint":false},{"pmid":"8666774","id":"PMC_8666774","title":"CD95 (Fas/Apo-1)-induced apoptosis results in loss of glucose transporter function.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8666774","citation_count":44,"is_preprint":false},{"pmid":"9725212","id":"PMC_9725212","title":"Protein kinase C regulates Fas (CD95/APO-1) expression.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9725212","citation_count":44,"is_preprint":false},{"pmid":"7543423","id":"PMC_7543423","title":"APO-1(CD95)-mediated apoptosis in Jurkat cells does not involve src kinases or CD45.","date":"1995","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/7543423","citation_count":44,"is_preprint":false},{"pmid":"9159204","id":"PMC_9159204","title":"Soluble Fas/Apo-1 splicing variants and apoptosis.","date":"1996","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/9159204","citation_count":41,"is_preprint":false},{"pmid":"9040002","id":"PMC_9040002","title":"Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro.","date":"1997","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9040002","citation_count":41,"is_preprint":false},{"pmid":"9935158","id":"PMC_9935158","title":"Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9935158","citation_count":40,"is_preprint":false},{"pmid":"9889415","id":"PMC_9889415","title":"The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis.","date":"1998","source":"European cytokine network","url":"https://pubmed.ncbi.nlm.nih.gov/9889415","citation_count":40,"is_preprint":false},{"pmid":"9378990","id":"PMC_9378990","title":"Fas (CD95, APO-1) antigen expression and function in murine mast cells.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9378990","citation_count":39,"is_preprint":false},{"pmid":"9692873","id":"PMC_9692873","title":"Differential regulation of CD95 (Fas/APO-1) expression in human blood eosinophils.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9692873","citation_count":38,"is_preprint":false},{"pmid":"9815617","id":"PMC_9815617","title":"Expression of fas (CD95/APO-1) antigen induced by radiation therapy for diffuse B-cell lymphoma: immunohistochemical study.","date":"1997","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/9815617","citation_count":38,"is_preprint":false},{"pmid":"19615968","id":"PMC_19615968","title":"Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19615968","citation_count":37,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46854,"output_tokens":6750,"usd":0.120906,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15859,"output_tokens":6009,"usd":0.11476,"stage2_stop_reason":"end_turn"},"total_usd":0.235666,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Upon APO-1/Fas (CD95) oligomerization, cytotoxicity-dependent APO-1-associated proteins (CAP1-4) are recruited to form a death-inducing signaling complex (DISC) with the aggregated receptor. CAP1 and CAP2 were identified as serine-phosphorylated MORT1/FADD. Association required the C-terminal cytoplasmic tail of APO-1 and was abolished by the lpr(cg) amino acid replacement in the death domain.\",\n      \"method\": \"Immunoprecipitation of APO-1-associated proteins from T and B cell lines after receptor crosslinking; mutant receptor analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP from endogenous proteins, multiple cell lines, functional domain mapping with mutants; foundational DISC paper replicated extensively\",\n      \"pmids\": [\"8521815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The NMR solution structure of the Fas death domain was determined: it consists of six antiparallel amphipathic alpha-helices in a novel fold. Site-directed mutagenesis identified the surface region involved in death-domain self-association and in binding to the downstream signaling partner FADD.\",\n      \"method\": \"NMR spectroscopy; site-directed mutagenesis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure determination combined with mutagenesis in a single rigorous study; directly establishes binding interface\",\n      \"pmids\": [\"8967952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Two distinct CD95 signaling pathways exist: in Type I cells, caspase-8 is activated rapidly and in large amounts at the DISC, bypassing mitochondria (Bcl-2/Bcl-xL overexpression does not block apoptosis); in Type II cells, DISC formation is reduced, caspase activation depends on mitochondrial membrane potential loss (ΔΨm), and Bcl-2/Bcl-xL overexpression blocks both caspase activation and apoptosis.\",\n      \"method\": \"Kinetic caspase activation assays, Bcl-2/Bcl-xL overexpression, DISC immunoprecipitation, caspase-3 reconstitution in MCF7-Fas cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (DISC IP, caspase assays, genetic overexpression, reconstitution), replicated across multiple cell lines; foundational paper with >2400 citations\",\n      \"pmids\": [\"9501089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CD95 crosslinking activates an acidic sphingomyelinase (optimal pH 5.0), causing sphingomyelin hydrolysis and ceramide generation. Cell-permeant ceramide analogue C2-ceramide was sufficient to induce apoptosis in CD95-sensitive lines, suggesting ceramide is an early intracellular signal downstream of CD95.\",\n      \"method\": \"In vivo sphingomyelin hydrolysis assay; direct in vitro enzymatic activity measurement with labeled SM vesicles; ceramide treatment\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct enzymatic assay plus functional rescue with ceramide, single lab; later work showed aSMase is not required in all contexts\",\n      \"pmids\": [\"7523573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TCR-induced apoptosis in human T cells (Jurkat, alloreactive clone S13, peripheral activated T cells) is mediated by autocrine CD95L: TCR stimulation induces CD95L expression and secretion of soluble CD95L, and apoptosis is blocked by anti-APO-1 antibody fragments or soluble APO-1 receptor decoys.\",\n      \"method\": \"Functional blocking antibodies; single-cell cultures; soluble receptor decoy competition; CD95L detection in supernatant\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal blocking approaches in multiple human T cell systems; replicated across three T cell models\",\n      \"pmids\": [\"7530335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Cell surface expression of APO-1 ligand (FasL) is regulated by Zn2+-dependent metalloproteases: metalloprotease inhibitors increase surface FasL accumulation, indicating that metalloprotease cleavage generates the soluble form of FasL and limits membrane-bound FasL.\",\n      \"method\": \"Immunofluorescence with class-specific protease inhibitors; antibody detection of soluble FasL; Zn2+/Ca2+ modulation\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological inhibitor approach in multiple T cell lines, consistent results, but mechanism inferred from inhibitors rather than direct identification of the metalloprotease\",\n      \"pmids\": [\"7545118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"p53 transcriptionally activates the CD95 receptor gene by binding to a p53-responsive element in the first intron of CD95 and cooperating with promoter elements, thereby upregulating CD95 surface expression in response to DNA-damaging anticancer drugs. This sensitizes cells to CD95-mediated apoptosis. Mutant p53 failed to induce CD95 upregulation.\",\n      \"method\": \"Reporter gene assays with p53-RE constructs; p53 binding assays; restitution of wt p53 in p53-null cells; temperature-sensitive p53 mutants\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — transcriptional activation demonstrated by multiple reporter constructs, direct p53 binding, functional rescue in p53-null cells, and temperature-sensitive mutant validation\",\n      \"pmids\": [\"9841917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CD95 engagement activates NF-κB DNA-binding activity independently of its cytotoxic function: a C-terminal 37-amino-acid deletion in the CD95 cytoplasmic domain that abrogates apoptosis only marginally affects NF-κB activation.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA); deletion mutant analysis in multiple cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus defined deletion mutant, multiple cell lines, single lab\",\n      \"pmids\": [\"8621545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CD95-triggered activation of stress-activated protein kinases (JNK/SAPK, 46 kDa and 54 kDa) occurs downstream of ICE-like proteases (caspases) and downstream of DISC formation: caspase inhibitor zVAD-fmk and CrmA blocked SAP kinase activation but not DISC formation, placing caspases between DISC and SAP kinases.\",\n      \"method\": \"Kinase assays (phosphorylation of c-Jun); caspase inhibitor (zVAD-fmk, CrmA overexpression); DISC immunoprecipitation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological epistasis with DISC and caspase assays, single lab, two orthogonal inhibitor approaches\",\n      \"pmids\": [\"8950975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The FasL homotrimer binds three Fas molecules. Point mutations at the FasL–Fas interaction interface (P206, Y218, F275/gld) reduced or abolished Fas binding and cytotoxicity; F275L (gld equivalent) caused aggregation and loss of Fas binding. Glycosylation of FasL N-linked glycans was required for efficient secretion.\",\n      \"method\": \"Site-directed mutagenesis of FasL; binding assays with recombinant Fas-Fc fusion; cytotoxicity assays; molecular modeling based on LTα–TNFRI structure\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with functional validation (binding + cytotoxicity), single lab\",\n      \"pmids\": [\"9228058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In autoimmune lymphoproliferative syndrome (ALPS), heterozygous CD95 death-domain mutations cause structural alterations that abolish FADD/MORT1 binding. Despite heterozygosity, lymphocytes from ALPS patients show markedly reduced FADD association and loss of caspase recruitment after CD95 crosslinking, establishing dominant-negative interference with DISC formation.\",\n      \"method\": \"Co-IP of FADD with CD95 from patient lymphocytes; caspase recruitment assay; structural analysis of nine independent death-domain mutations\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP from primary patient cells across nine independent mutations, with functional caspase recruitment assay; directly establishes mechanism of dominant-negative interference\",\n      \"pmids\": [\"10200300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Ceramide links cellular stress responses (gamma-irradiation, doxorubicin) to CD95-mediated apoptosis: ceramide induces CD95L expression and apoptosis; antisense CD95L and dominant-negative FADD block ceramide-induced and stress-induced apoptosis. Fibroblasts from Niemann-Pick type A patients (lacking ceramide synthesis) fail to upregulate CD95L and resist apoptosis after irradiation/doxorubicin but can still undergo apoptosis when directly triggered through CD95.\",\n      \"method\": \"Antisense CD95L; dominant-negative FADD transfection; genetically deficient NPA fibroblasts; exogenous ceramide rescue\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function (NPA cells, dominant-negative FADD), rescue with exogenous ceramide; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"9321399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Fas/CD95-triggered acidic sphingomyelinase activation, ceramide release, and subsequent JNK/p38 kinase activation are regulated downstream of caspases: caspase inhibition (Ac-YVAD-cmk or CrmA) prevented aSMase activation and ceramide generation, placing caspases upstream of aSMase in the CD95 signaling cascade.\",\n      \"method\": \"Caspase inhibitor (Ac-YVAD-cmk); CrmA transfection; aSMase activity assay; ceramide measurement; JNK/p38 kinase assay\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic (CrmA) caspase inhibition with direct aSMase activity measurement; single lab, two inhibitor approaches\",\n      \"pmids\": [\"10200443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Acid sphingomyelinase (aSMase) is required for Fas-mediated cell death in hepatocytes but not in thymocytes, T cells, or B cells: aSMase-/- mice showed protection from anti-Fas-induced hepatocyte apoptosis and mortality, while lymphocyte apoptosis and activation-induced cell death were unaffected by aSMase status.\",\n      \"method\": \"Genetically engineered aSMase-/- mice; in vitro and in vivo anti-Fas antibody challenge; comparison of hepatocyte vs. lymphocyte apoptosis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetically engineered knockout mice, multiple cell types compared, in vivo and in vitro validation; directly establishes tissue-specific role of aSMase\",\n      \"pmids\": [\"10722706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Ceramide generation downstream of CD95 is initiator-caspase-dependent and occurs during the initiation phase of apoptosis, prior to the effector phase: dominant-negative FADD blocked ceramide generation; CrmA blocked FADD-induced ceramide elevation; limited pro-caspase-8 expression raised ceramide without causing apoptosis.\",\n      \"method\": \"Titrated FADD transfection in HeLa and 293T cells; dominant-negative FADD; CrmA; diacylglycerol kinase assay; electrospray tandem mass spectrometry for ceramide\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution approach with dominant-negative FADD and limited caspase-8 expression, confirmed by mass spectrometry; single lab\",\n      \"pmids\": [\"10722705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"FAP-1 (Fas-associated phosphatase 1) binds the C-terminus of Fas and retains it intracellularly within the cytoskeleton network, reducing cell surface Fas expression. Dominant-negative FAP-1 or FAP-1 siRNA upregulates surface Fas. A Fas C275 mutation decreases FAP-1 association and increases Fas surface export.\",\n      \"method\": \"FAP-1 overexpression/dominant-negative transfection; siRNA knockdown; flow cytometry for surface Fas; confocal microscopy; mutation analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic perturbations (overexpression, dominant-negative, siRNA) with direct surface expression readout; single lab, two orthogonal approaches\",\n      \"pmids\": [\"12724420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FAS/CD95 mediates noncanonical IL-1β and IL-18 maturation in macrophages and dendritic cells via caspase-8 activation, independently of inflammasomes or RIP3. TLR ligand priming upregulates Fas expression and renders cells responsive to FasL-mediated caspase-8 activation and IL-1β/IL-18 processing.\",\n      \"method\": \"Genetic knockout cells (RIP3-/-, caspase-1-/-); FasL stimulation of macrophages and DCs; IL-1β/IL-18 maturation assay; caspase-8 activation assay\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic knockouts (inflammasome, RIP3) with direct cytokine maturation and caspase-8 activation readouts; establishes novel non-apoptotic pathway\",\n      \"pmids\": [\"23144495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Fas/CD95-induced apoptosis is accompanied by production of chemokines (MCP-1, IL-8, CXCL1, IL-6, GMCSF) that serve as 'find-me' signals promoting phagocyte chemotaxis toward apoptotic cells. RIPK1 and IAPs are required for optimal Fas-induced cytokine/chemokine production; IAP antagonists suppress this proinflammatory response.\",\n      \"method\": \"Cytokine/chemokine profiling after Fas stimulation; chemotaxis assay; RIPK1 knockdown; IAP antagonist treatment; phagocyte recruitment assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional chemotaxis assay linked to specific mediators; genetic (RIPK1 KD) and pharmacological (IAP antagonist) perturbations; single lab\",\n      \"pmids\": [\"23434371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Nitric oxide (NO) inhibits APO-1/Fas-mediated apoptosis by S-nitrosylating caspase-8 and caspase-1, preventing their activation. NO blocks proteolytic cleavage of caspase-3 upstream of its activation. The effect is cGMP-independent and also inhibits apoptosis induced by FADD overexpression.\",\n      \"method\": \"NO donor and inducible NOS transfection; caspase-3 cleavage assay; caspase-8 S-nitrosylation assay; FADD overexpression apoptosis assay; 8-bromo-cGMP control\",\n      \"journal\": \"Cell growth & differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct caspase S-nitrosylation demonstrated, multiple mechanistic levels tested; single lab\",\n      \"pmids\": [\"9607562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Human and mouse Fas/CD95 genes each contain a p53-responsive element (p53RE) in the first intron that is specifically bound by p53 and functions as a p53-dependent enhancer. Unlike the bax p53RE, the Fas p53RE is activated by p53 mutants that cannot induce apoptosis (Pro-175 and Ala-143), suggesting Fas upregulation by p53 sensitizes to apoptosis rather than directly inducing it.\",\n      \"method\": \"Reporter gene assays in mammalian and yeast systems; p53 binding assays; discriminatory p53 mutant analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct p53 binding and transcriptional activation assays with defined mutants; functional distinction from bax established; single lab\",\n      \"pmids\": [\"10660538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TAp63 and TAp73 isoforms of the p53 family, in addition to wt p53, transactivate the CD95/FAS gene through the intronic p53-responsive element and promoter p53-REs, with cooperation between intronic and promoter elements required for maximal transcriptional activation.\",\n      \"method\": \"Reporter gene assays with p53-RE constructs; p63/p73 isoform expression\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct transcriptional reporter assay with defined p53-family members; single lab, single method\",\n      \"pmids\": [\"19615968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A novel ubiquitin-conjugating enzyme (UBC-FAP/HsUbc9) associates with the Fas death domain. A single amino acid substitution in the Fas death domain that abolishes apoptosis also abolishes Fas–UBC-FAP association, suggesting UBC-FAP may participate in Fas signal transduction.\",\n      \"method\": \"Yeast two-hybrid screen; co-immunoprecipitation; complementation of ubc9-1 yeast mutant; death-domain point mutant analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single pulldown/Co-IP with no downstream functional validation of the interaction in Fas signaling; association correlates with apoptosis competence but causality not established\",\n      \"pmids\": [\"8940097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CD47 (integrin-associated protein) physically associates with Fas upon Fas activation and augments Fas-mediated apoptosis: Jurkat cells lacking CD47 are resistant to Fas-mediated death and show impaired caspase activation, cytochrome c release, loss of mitochondrial membrane potential, and DNA cleavage downstream of Fas engagement.\",\n      \"method\": \"CD47-deficient Jurkat cells; anti-Fas co-immunoprecipitation showing Fas–CD47 association; caspase and PARP cleavage assays; mitochondrial membrane potential assay; CD47-null primary mouse T cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP showing direct association plus loss-of-function phenotype in both cell lines and primary CD47-/- T cells; single lab\",\n      \"pmids\": [\"15917238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Protein kinase C (PKC) inhibits CD95 receptor oligomerization at the cell surface as a mechanism for restraining CD95-mediated apoptosis; PKC activation diminishes CD95 aggregation induced by agonistic antibodies and UVB-induced CD95 oligomerization and apoptosis in Jurkat T cells.\",\n      \"method\": \"PKC activators (PMA) and inhibitors; CD95 aggregation assay; UVB-induced apoptosis; MAP kinase pathway inhibition\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor oligomerization directly measured with pharmacological modulation plus two independent stimuli (agonist Ab and UV); single lab\",\n      \"pmids\": [\"10528172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Fas-mediated apoptosis in primary mouse T cells, B cells, and dendritic cells requires receptor palmitoylation at Cys194 for lipid raft localization: a palmitoylation-defective Fas C194V mutant fails to efficiently induce apoptosis in primary immune cells despite retaining ability to enhance T-cell differentiation and to prevent lymphoaccumulation and autoimmunity.\",\n      \"method\": \"Knock-in C194V mutant mice; palmitoylation assay; lipid raft fractionation; apoptosis assays in primary immune cells; lymphoproliferation phenotype analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knock-in mutant with multiple primary cell types tested, multiple functional readouts (apoptosis, raft localization, autoimmunity); single lab but multiple orthogonal methods\",\n      \"pmids\": [\"28008916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Fas (CD95) ligation on human monocytes induces proinflammatory cytokine (TNF-α, IL-8) production and NF-κB nuclear translocation through a caspase-dependent mechanism, while in monocyte-derived macrophages Fas-induced cytokine responses occur without apoptosis and are caspase-independent, demonstrating maturation-dependent divergence in Fas signaling.\",\n      \"method\": \"Fas ligation on primary monocytes and macrophages; ELISA for TNF-α and IL-8; NF-κB nuclear translocation; caspase inhibitor treatment; neutrophil chemotaxis assay\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary human cells with pharmacological dissection; two distinct cell maturation states compared; single lab\",\n      \"pmids\": [\"12794152\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FAS/CD95 is a death receptor that, upon oligomerization by FasL, recruits FADD/MORT1 via death-domain interactions to form the DISC (death-inducing signaling complex), which activates caspase-8; in Type I cells sufficient caspase-8 at the DISC directly activates effector caspase-3 independent of mitochondria, whereas in Type II cells limited DISC activity requires amplification through the mitochondrial pathway (sensitive to Bcl-2/Bcl-xL); FAS surface expression is transcriptionally induced by p53 (and TAp63/TAp73) via intronic and promoter p53-responsive elements, regulated post-translationally by FAP-1 (which retains Fas intracellularly) and palmitoylation at Cys194 (required for lipid raft localization and efficient apoptosis in primary immune cells); CD95 additionally triggers non-apoptotic signals including NF-κB activation, JNK/SAP kinase activation (via caspases), ceramide generation (via caspase-dependent aSMase activation, tissue-dependent), and caspase-8-dependent maturation of IL-1β/IL-18 in myeloid cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FAS (APO-1/CD95) is a death-domain-containing receptor that initiates apoptosis when oligomerized by trimeric FasL, nucleating a death-inducing signaling complex (DISC) in which the receptor C-terminal cytoplasmic tail recruits serine-phosphorylated FADD/MORT1 and downstream caspase-8 [#0, #9]. NMR structure determination of the Fas death domain (six antiparallel amphipathic α-helices) mapped the self-association and FADD-binding surface, and disruption of this interface—by the lpr(cg) substitution or by death-domain mutations—abolishes FADD recruitment and signaling [#1, #0]. Heterozygous death-domain mutations that block FADD binding cause autoimmune lymphoproliferative syndrome (ALPS) through dominant-negative interference with DISC formation [#10]. Two signaling tiers exist: in Type I cells abundant DISC-generated caspase-8 directly drives effector caspases independently of mitochondria, whereas in Type II cells limited DISC activity requires mitochondrial amplification and is blocked by Bcl-2/Bcl-xL [#2]. FAS surface availability is set transcriptionally—p53, and the family members TAp63/TAp73, transactivate FAS via an intronic p53-responsive element cooperating with promoter elements, sensitizing cells to apoptosis [#6, #19, #20]—and post-translationally, with FAP-1 retaining Fas intracellularly to limit surface expression and Cys194 palmitoylation required for lipid-raft localization and efficient apoptosis in primary immune cells [#15, #24]. Beyond death, FAS triggers non-apoptotic outputs including caspase-dependent JNK/SAPK activation, caspase-dependent acidic-sphingomyelinase activation and ceramide generation that is tissue-restricted (required in hepatocytes but not lymphocytes), NF-κB activation, and caspase-8-dependent maturation of IL-1β/IL-18 in myeloid cells [#8, #12, #13, #16].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established that CD95 engagement generates a lipid second messenger, linking receptor ligation to ceramide-based signaling before the DISC was defined.\",\n      \"evidence\": \"In vivo and in vitro acidic sphingomyelinase activity assays plus C2-ceramide treatment in CD95-sensitive lines\",\n      \"pmids\": [\"7523573\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not place aSMase activation relative to caspases\", \"Tissue dependence of ceramide requirement not addressed\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined the physical basis of FAS signal initiation by identifying the DISC and FADD/MORT1 as the recruited adaptor, answering how an oligomerized receptor transmits a death signal.\",\n      \"evidence\": \"Co-IP of APO-1-associated proteins after receptor crosslinking in T/B cell lines with mutant receptor mapping\",\n      \"pmids\": [\"8521815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Caspase-8 not yet shown as the enzymatic effector at the DISC\", \"Quantitative differences between cell types not resolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrated that FAS drives physiological activation-induced T cell death via an autocrine FasL loop, defining a functional context for the pathway.\",\n      \"evidence\": \"Blocking antibody fragments and soluble receptor decoys in Jurkat and primary T cell systems\",\n      \"pmids\": [\"7530335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address surface vs soluble ligand control\", \"In vivo relevance beyond cultured T cells not tested here\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Showed that membrane FasL availability is post-translationally controlled by metalloprotease shedding, distinguishing membrane-bound from soluble ligand.\",\n      \"evidence\": \"Class-specific protease inhibitors with detection of soluble FasL in T cell lines\",\n      \"pmids\": [\"7545118\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The responsible metalloprotease was not directly identified\", \"Mechanism inferred pharmacologically\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Provided the atomic structure of the Fas death domain and mapped the interaction surface, explaining how DISC-disrupting mutations act.\",\n      \"evidence\": \"NMR solution structure with site-directed mutagenesis\",\n      \"pmids\": [\"8967952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the death-domain:FADD complex not solved here\", \"Higher-order oligomer geometry not defined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Separated FAS apoptotic from non-apoptotic signaling by showing NF-κB activation persists when a cytotoxicity-required tail segment is deleted.\",\n      \"evidence\": \"EMSA with C-terminal deletion mutants across multiple cell lines\",\n      \"pmids\": [\"8621545\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Adaptors mediating the NF-κB branch not identified\", \"Physiological consequences not defined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identified a candidate death-domain-associated ubiquitin-conjugating enzyme (UBC-FAP/Ubc9), raising the possibility of conjugation enzymes in FAS signaling.\",\n      \"evidence\": \"Yeast two-hybrid and co-IP with death-domain point mutant correlation\",\n      \"pmids\": [\"8940097\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single pulldown without functional validation of the interaction in FAS signaling\", \"Causal role in apoptosis not established\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Placed JNK/SAPK activation downstream of caspases and the DISC, ordering a stress-kinase branch of FAS signaling.\",\n      \"evidence\": \"c-Jun kinase assays with zVAD-fmk/CrmA epistasis and DISC IP\",\n      \"pmids\": [\"8950975\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The specific caspase and kinase intermediates not pinned down\", \"Downstream transcriptional outputs not mapped\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined the FasL trimer–Fas binding stoichiometry and interface, and the glycosylation requirement for ligand secretion.\",\n      \"evidence\": \"FasL mutagenesis with Fas-Fc binding and cytotoxicity assays, modeled on LTα–TNFRI\",\n      \"pmids\": [\"9228058\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No co-crystal structure of the Fas–FasL complex\", \"Single lab, modeling-based interface\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Connected genotoxic stress to FAS by showing ceramide induces CD95L expression and FADD-dependent apoptosis, embedding FAS in a stress-response loop.\",\n      \"evidence\": \"Antisense CD95L, dominant-negative FADD, and Niemann-Pick A fibroblasts with ceramide rescue\",\n      \"pmids\": [\"9321399\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor-level apoptosis remained intact in NPA cells, limiting generality\", \"Quantitative ceramide thresholds not defined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Resolved the Type I/Type II dichotomy, explaining why mitochondrial amplification (and Bcl-2 sensitivity) governs apoptosis in some cells but not others.\",\n      \"evidence\": \"Kinetic caspase assays, Bcl-2/Bcl-xL overexpression, DISC IP, and caspase-3 reconstitution in MCF7-Fas cells\",\n      \"pmids\": [\"9501089\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular determinant of Type I vs Type II identity not defined here\", \"Did not identify what limits DISC formation in Type II cells\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Established p53 as a transcriptional inducer of FAS through an intronic p53-RE, linking DNA-damage responses to FAS-mediated drug sensitivity.\",\n      \"evidence\": \"Reporter assays, p53 binding, wt-p53 restitution in p53-null cells, and temperature-sensitive mutants\",\n      \"pmids\": [\"9841917\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not separate sensitization from direct induction\", \"Other transcription factors at the locus not surveyed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified NO-mediated S-nitrosylation of caspase-8/-1 as a brake on FAS apoptosis acting at the caspase level.\",\n      \"evidence\": \"NO donors and iNOS transfection with caspase cleavage and S-nitrosylation assays, cGMP-independent\",\n      \"pmids\": [\"9607562\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological NO sources controlling FAS not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed PKC restrains FAS by inhibiting receptor oligomerization at the surface, defining a pre-DISC regulatory node.\",\n      \"evidence\": \"PKC activators/inhibitors with CD95 aggregation and UVB-apoptosis readouts in Jurkat cells\",\n      \"pmids\": [\"10528172\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PKC substrate on the oligomerization machinery not identified\", \"Single cell system\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Ordered the ceramide branch by placing aSMase activation downstream of initiator caspases during the initiation phase of apoptosis.\",\n      \"evidence\": \"Dominant-negative FADD and CrmA with aSMase activity, ceramide, and JNK/p38 assays; titrated caspase-8 expression and mass spectrometry\",\n      \"pmids\": [\"10200443\", \"10722705\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct caspase substrate activating aSMase not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined the ceramide pathway as tissue-restricted, showing aSMase is required for FAS-induced hepatocyte but not lymphocyte death.\",\n      \"evidence\": \"aSMase-/- mice challenged with anti-Fas in vivo and in vitro, comparing hepatocytes and lymphocytes\",\n      \"pmids\": [\"10722706\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the hepatocyte-specific requirement not defined\", \"Did not address aSMase role in non-apoptotic FAS signaling\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showed the intronic FAS p53-RE is engaged even by apoptosis-defective p53 mutants, distinguishing FAS as a sensitization rather than direct apoptosis-inducing target.\",\n      \"evidence\": \"Reporter and p53 binding assays in mammalian and yeast systems with discriminatory p53 mutants\",\n      \"pmids\": [\"10660538\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous chromatin context not tested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified FAP-1 as a post-translational regulator that retains Fas intracellularly and limits surface expression, with Cys275 controlling the interaction.\",\n      \"evidence\": \"FAP-1 overexpression, dominant-negative, and siRNA with surface-Fas flow cytometry, confocal microscopy, and mutation analysis\",\n      \"pmids\": [\"12724420\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of cytoskeletal retention not detailed\", \"In vivo relevance not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Revealed maturation-dependent divergence of FAS signaling in myeloid cells: caspase-dependent cytokine output in monocytes versus caspase-independent responses in macrophages.\",\n      \"evidence\": \"Fas ligation on primary monocytes/macrophages with cytokine ELISA, NF-κB translocation, and caspase inhibitors\",\n      \"pmids\": [\"12794152\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular switch underlying maturation-state divergence not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified CD47 as a Fas-associated co-factor that augments Fas apoptosis via the mitochondrial branch.\",\n      \"evidence\": \"CD47-deficient Jurkat and CD47-null primary T cells with Fas–CD47 co-IP, caspase/PARP cleavage, cytochrome c release, and ΔΨm assays\",\n      \"pmids\": [\"15917238\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the Fas–CD47 association is direct vs complex-mediated not resolved\", \"Structural basis not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established a non-apoptotic FAS function: caspase-8-dependent IL-1β/IL-18 maturation in myeloid cells independent of inflammasomes or RIP3.\",\n      \"evidence\": \"RIP3-/- and caspase-1-/- cells with FasL stimulation, cytokine maturation, and caspase-8 activation assays\",\n      \"pmids\": [\"23144495\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct caspase-8 substrate for cytokine processing not pinned down\", \"In vivo contribution to inflammation not quantified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed FAS-induced apoptosis is proinflammatory, generating chemokine 'find-me' signals requiring RIPK1 and IAPs.\",\n      \"evidence\": \"Cytokine/chemokine profiling, chemotaxis and phagocyte recruitment assays with RIPK1 knockdown and IAP antagonists\",\n      \"pmids\": [\"23434371\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coupling RIPK1/IAPs to specific chemokines not detailed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that Cys194 palmitoylation drives Fas into lipid rafts and is required for efficient apoptosis in primary immune cells, separating death from non-apoptotic functions in vivo.\",\n      \"evidence\": \"C194V knock-in mice with palmitoylation assay, raft fractionation, primary-cell apoptosis, and autoimmunity phenotyping\",\n      \"pmids\": [\"28008916\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The palmitoyl transferase acting on Fas not identified\", \"How raft localization mechanistically enhances DISC assembly not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular determinant that assigns cells to Type I versus Type II FAS signaling, and the rules governing the switch between apoptotic and the diverse non-apoptotic outputs (NF-κB, JNK, ceramide, cytokine maturation), remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined factor predicting Type I vs Type II identity\", \"Switch between death and inflammatory/proliferative outputs not mechanistically specified\", \"Palmitoyl transferase and raft-assembly machinery for Fas unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [15, 24, 23]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 2, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 16, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 8]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 19, 20]}\n    ],\n    \"complexes\": [\"DISC (death-inducing signaling complex)\"],\n    \"partners\": [\"FADD\", \"FasL\", \"FAP1\", \"CD47\", \"CASP8\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}